Sunday, 22 July 2018 - 15:46
  • it
  • de
  • en
  • fr

Stada

BMS hires banks to put French OTC division on sale (€1bn)

Reuters has reported that Bristol-Myers Squibb has hired Deutsche Bank and Jefferies to look for buyers of its French division producing and marketing OTCs, worth over €1bn. The French asset delivered sales of €425m in 2017 and has 1,500 employees….

Stada could now target Hikma

German generics manufacturer Stada could target competitor Hikma, according to a statement by CEO Claudio Albrecht reported by The Sunday Telegraph. Albrecht has reportedly said that his company is seeking acquisitions and is targeting UK companies. The two most likely…

Stada introduces new group’s strategy

Stada pharmaceutical group today has announced its new strategy to investors for the first time after being acquired by PEs Bain Capital and Cinven. Simultaneously, the company has reported its 2017 financial results. The new strategy includes business internationalization, by…

CEO Claudio Albrecht announces new strategy for Stada

German weekly WirtschaftsWoche this week published a long interview to Claudio Albrecht, newly-appointed CEO of German pharmaceutical group Stada. The new chief executive has soon directed extreme criticism at the previous management, accusing it of inability to control the chaos…

Stada appoints all top managers

As part of a restructuring plan for recently-acquired Stada – the third German drugmaker – Bain Capital and Cinven funds have appointed Günter von Au, former Süd-Chemie head, as head of Stada’s Supervisory Board (Aufsichtsrat), and Claudio Albrecht, former Ratiopharm…

The never-ending process of acquiring Stada

The attempt to take over Stada by private equities Bain Capital and Cinven seems unending.  The US-based fund Elliott Management ($33bn in investments) – the major stakeholder in the Germany-based group – yesterday announced it is ready to sell its…

Further details on €5.3bn takeover of Stada

63.85% of shareholders in Stada – the minimum acceptance threshold being 63% – last week approved the €5.3bn acquisition by investment funds Cinven and Bain Capital. Shareholders who have not yet tendered their shares will have a further acceptance period…

Stada successfully acquired for €5.3bn

Shareholders of Germany-based generics producer Stada gave the green light to the consortium comprising investment funds Bain Capital and Cinven to acquire the company for €5.3bn. The minimum acceptance threshold had been set to 63%. It was reached on August…

New €4.1bn offer for Stada by Bain & Cinven consortium

Stada received this evening a new offer by the consortium created by private equities Cinven and Bain Capital. The consortium increased its previous offer to €4.1bn – €66.25 per share. The new offer is now subject to approval by shareholders,…

Bain Capital and Cinven prepare new €5.3bn bid for Stada

The consortium created by PEs Bain Capital and Cinven is planning to submit to Stada’s board a new takeover offer which improves by €0.25 the previous bid – €66 per share. The new offer will be subject to approval by…

Revolution in Stada’s board: CEO and CFO leave

The supervisory board (Aufsichtsrat) of the German pharmaceutical group Stada accepted the resignations for personal reasons by CEO Matthias Wiedenfels and by CFO Helmut Kraft. Engelbert Coster Tjeenk Willink, a long-standing executive in the German drugmaking industry – formerly at…

Stada’s shareholders reject €4.1bn acquisition

Stada’s shareholders rejected the €4.1bn acquisition offer by private equities Bain Capital and Cinven. The acceptance ratio for the sale did not reach the threshold of 67.5% of shares, that is only 2 percentage points over the 65.52% acceptance on…

Stada sold to Bain Capital-Cinven consortium for €4.1bn

Private equities Bain Capital and Cinven won the battle to acquire Stada through a €4.1bn offer. This is what the board of the German drugmaker announced today on a press release, specifying they will recommend to shareholders to accept the…

Bids for Valeant’s Inova not meeting expectations

Valeant Pharmaceuticals, owner of iNova, is reportedly dissatisfied with the three bids it has so far received for its subsidiary. It is believed that offers have come in at around AUD900m (USD 686.5m), below the expected minimum of one billion…

Final stages of the battle for control of Stada

The battle to acquire German drugmaker Stada is edging towards a close. Reuters reported today that final offers from the two remaining bidders – the consortium comprising private equities Advent and Permira and the consortium comprising Bain and Cinven –…

Stada rejects €3.7bn bid by private equity consortia

Stada board announced in a communication to Frankfurt stock exchange authorities that it has rejected both €3.7bn bids placed by two private equity consortia. Stada management objected that the bids do not reflect the company’s value and potential. Stada, however,appears…

Here are the first formal bids for Stada (€3.7bn)

Two private equity consortia submitted their takeover offers for German drug maker Stada. They both valued the group at €3.7bn, that is €58 per share. A consortium comprises PEs Advent International and Permira and one comprises Bain Capital and Cinven….

Fosun Pharmaceutical ready to make a bid for Stada

Reuters reported today, quoting people close to the matter, that Shanghai Fosun Pharmaceutical is about to place an offer for Stada, and possibly in Joint Venture with a buyout fund like CVC. Fosun Pharma is part of Fosun International, a…

Four private equities now targeting Stada

Private equities Advent and Permira are ready to place their bids for Germany-based pharmaceutical group Stada, valued at approximately €4.8bn, Reuters reported, citing people familiar with the matter. Private equities Bain Capital and Cinven also have a strong interest in…

At last, Advent’s official bid for Stada: €58 per share (€3.6bn)

German pharmaceutical group Stada informed the stock-market regulatory authorities it has received a binding offer by investor Advent International, which has valued the Bad Vilbel-based company approximately €3.6bn in cash, which equals €58 per share. Advent has also offered to…

Third company approaches Stada

Stada announced on a press release it has received another non-binding offer, without disclosing the potential buyer’s name. The German group added that the new bid is of approximately €58.00 per share, which corresponds to valuing the group at approximately…

Stada in the midst of an M&A contest

Germany-based pharmaceutical group Stada confirmed today in a press release it has been approached by private equity Cinven Partners LLP and another group whose name has not been disclosed. Both groups have submitted a non-binding offer to Stada and, specifically,…

Stada and Mundipharma targeting iNova

Germany’s STADA Arzneimittel AG and Mundipharma International are among the bidders for Australia-based iNova, owned by Valeant group. The news was reported by the weekly Australian Financial Review, which also informed that GSK has apparently lost interest in an acquisition….

Stada targeted by Mylan and Novartis

Germany-based pharmaceutical group Stada Arzneimittel is reportedly targeted by Novartis and Mylan. The rumors, which started circulating in London, mention a defense strategy against takeover bids developed by Goldman Sachs bank, which was hired by the pharmaceutical group’s board. Stada…

Stada makes acquisition in the UK

Germany-based pharmaceutical group Stada will enlarge its product portfolio by acquiring UK-based manufacturer of vitamins and food supplements Natures Aid. Natures Aid is headquartered in Preston (Manchester) and has approximately 60 employees. The company generated a revenue of approximately GBP7.3m…